Nasdaq
$3.36▲ 1.82%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $174.5MShares out 51.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 9.28After-hours26.09.29 05:478-KKey event#●●●#●●●#●●●
Camp4 Therapeutics Corp
Camp4 Therapeutics announced its Phase 1/2 ASCEND clinical trial plan for CMP-002 in SYNGAP1-related disorders during its Analyst Day on September 28, 2026. The company expects to dose the first patient by the end of 2026 and targets a topline data readout in the first half of 2028, while also providing updates on its SHANK3 preclinical program.…more
$3.36+1.82%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 08:504Ownership
Camp4 Therapeutics Corp
Insider Kelly Gold of Camp4 Therapeutics Corp reported a change in beneficial ownership of company securities as of August 31, 2026. This filing provides the details regarding the change in the insider's shareholdings via Form 4.…more
$3.36+1.82%vs prev closeView filingShare - 8.31After-hours26.09.01 06:06SCHEDULE 13D/AOwnership
Camp4 Therapeutics Corp
5AM Ventures VI, L.P. filed a Schedule 13D/A on August 31, 2026, to update its beneficial ownership status in Camp4 Therapeutics Corp. This filing serves as an official notification of changes in the company's equity structure by a major shareholder.…more
$3.36+1.82%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:00#●●●#●●●
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
CAMP4 Therapeutics announced its participation in a panel discussion at the 10th Annual Chardan Healthcare Conference on October 20, 2026. The company will discuss its progress in RNA medicine and transcriptome engineering during the event.…more
$3.36+1.82%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.10Pre-market26.09.10 20:33
●●●●●●●● ●●●●● ●●●●●●
CAMP4 Therapeutics has received authorization from the UK's MHRA to initiate a Phase 1/2 clinical trial for its SYNGAP1-related disorder candidate, CMP-002. The company plans to begin the study in the fourth quarter of 2026, building on previous regulatory clearances in Australia and Argentina.…more
$3.36+1.82%vs prev close - 9.8After-hours26.09.09 05:05
●●●●●●●● ●●●●● ●●●●●●
CAMP4 Therapeutics will host a virtual Analyst Day to discuss the clinical trial design for its SYNGAP1-related disorder treatment, CMP-002. The event will provide updates on the company's early discovery pipeline and the upcoming Phase 1/2 clinical trial.…more
$3.36+1.82%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report